References
- Ashley EA. Towards precision medicine. Nat Rev Genet 2016;17(9):507–522. https://doi.org/10.1038/nrg.2016.86
- Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372(9):793–795. https://doi.org/10.1056/NEJMp1500523
- Joo HJ, Ahn SG, Park JH, Park JY, Hong SJ, Kim SY, Choi WG, Gwon HC, Lim YH, Kim W, et al. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study. Sci Rep 2018;8(1). https://doi.org/10.1038/s41598-017-18134-y
- Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA 2010;304(16):1821–1830. https://doi.org/10.1001/jama.2010.1543
- Sorich MJ, Rowland A, McKinnon RA, Wiese MD. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: A meta-analysis. Circ Cardiovasc Genet 2014;7(6):895–902. https://doi.org/10.1161/CIRCGENETICS.114.000669
- Xi Z, Fang F, Wang J, AlHelal J, Zhou Y, Liu W. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis. Platelets 2019;30(2):229–240. https://doi.org/10.1080/09537104.2017.1413178
- Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94(3):317–323. https://doi.org/10.1038/clpt.2013.105
- Kheiri B, Osman M, Abdalla A, Haykal T, Pandrangi PV, Chahine A, Ahmed S, Osman K, Bachuwa G, Hassan M, et al. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. Catheterization Cardiovasc Interventions 2019;93(7):1246–1252. https://doi.org/10.1002/ccd.27949
- Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, Van’t Hof AWJ, Van Der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med 2019;381(17):1621–1631. https://doi.org/10.1056/NEJMoa1907096
- Liu J, Qin L, Xi S, Tong W, Yuan M, Peng L, Liu J, Wang X, Zhang Y, Yin T. Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI. Thromb Res 2019;179:87–94. https://doi.org/10.1016/j.thromres.2019.05.004
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJWV. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane; 2019. Available from www.training.cochrane.org/handbook
- Martin J, Williams AK, Klein MD, Sriramoju VB, Madan S, Rossi JS, Clarke M, Cicci JD, Cavallari LH, Weck KE, et al. Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. Genet Med 2020;22(1):160–169. https://doi.org/10.1038/s41436-019-0611-1
- Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv 2018;11(2):181–191. https://doi.org/10.1016/j.jcin.2017.07.022
- Lee CR, Sriramoju VB, Cervantes A, Howell LA, Varunok N, Madan S, Hamrick K, Polasek MJ, Lee JA, Clarke M, et al. Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. Circulation Genomic and Precision Medicine 2018;11(4):e002069. https://doi.org/10.1161/CIRCGEN.117.002069
- Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, et al. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. J Cardiol 2016;68(1):29–36. https://doi.org/10.1016/j.jjcc.2015.07.019
- Shen DL, Wang B, Bai J, Han Q, Liu C, Huang XH, Zhang JY. Clinical Value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population. J Cardiovasc Pharmacol 2016;67(3):232–236. https://doi.org/10.1097/FJC.0000000000000337
- Deiman BALM, Tonino PAL, Kouhestani K, Schrover CEM, Scharnhorst V, Dekker LRC, Pijls NHJ. Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands. Neth Heart J 2016;24(10):589–599. https://doi.org/10.1007/s12471-016-0873-z
- Dong P, Yang X, Bian S. Genetic polymorphism of CYP2C19 and inhibitory effects of ticagrelor and clopidogrel towards post-percutaneous coronary intervention (PCI) platelet aggregation in patients with acute coronary syndromes. Med Sci Monit 2016;22:4929–4936. https://doi.org/10.12659/MSM.902120
- Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet 2010;376(9749):1320–1328. https://doi.org/10.1016/S0140-6736(10)61274-3
- Sorich MJ, Vitry A, Ward MB, Horowitz JD, Mckinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thrombosis Haemostasis 2010;8(8):1678–1684. https://doi.org/10.1111/j.1538-7836.2010.03923.x
- 1000 Genomes Database. 2020. http://Www.1000Genomes.Org/. https://www.internationalgenome.org/ Accessed on 5/4/2020.
- Scinapse. 2019. https://scinapse.io/
- Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium. Circulation 2011;123(23):2736–2747. https://doi.org/10.1161/CIRCULATIONAHA.110.009449
- Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev 2016;5(1). https://doi.org/10.1186/s13643-016-0384-4
- Wells G, Shea B, O’Connell D, Peterson J. 2000. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17(1):1–12. https://doi.org/10.1016/0197-2456(95)00134-4
- Siller-Matula JM, Trenk D, Krähenbühl S, Michelson AD, Delle-Karth G. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thrombosis Haemostasis 2014;12(1):2–13. https://doi.org/10.1111/jth.12445
- Siller-Matula JM, Lang IM, Neunteufl T, Kozinski M, Maurer G, Linkowska K, Grzybowski T, Kubica J, Jilma B. Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. PLoS ONE 2014;9(7). https://doi.org/10.1371/journal.pone.0102701
- Fan ZG, Zhang WL, Xu B, Ji J, Tian NL, He SH. Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: A comprehensive meta-analysis. Drug Des Devel Ther 2019;13:719–730. https://doi.org/10.2147/DDDT.S196535
- Galimzhanov AM, Azizov BS. Ticagrelor for Asian patients with acute coronary syndrome in real-world practice: A systematic review and meta-analysis of observational studies. Indian Heart J 2019;71(1):15–24. https://doi.org/10.1016/j.ihj.2019.01.003
- Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001–2015. https://doi.org/10.1056/NEJMoa0706482
- Gross L, Trenk D, Jacobshagen C, Krieg A, Gawaz M, Massberg S, Baylacher M, Aradi D, Stimpfle F, Hromek J, et al. Genotype-phenotype association and impact on outcomes following guided de-escalation of anti-platelet treatment in acute coronary syndrome patients: the TROPICAL-ACS genotyping substudy. Thromb Haemost 2018;118(9):1656–1667. https://doi.org/10.1055/s-0038-1667337
- Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet 2012;51(5):305–318. https://doi.org/10.2165/11630960-000000000-00000
- Pereira NL 2020. Tailored antiplatelet initiation to lessen outcomes due to decreased clopidogrel response after percutaneous coronary intervention - TAILOR PCI. ACC 2020/WCC. https://www.acc.org/latest-in-cardiology/clinical-trials/2020/03/26/19/53/tailor-pci Accessed on 8/6/2020.
- Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel. clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49(14):1505–1516. https://doi.org/10.1016/j.jacc.2006.11.044
- Kheiri B, Osman M, Abdalla A, Haykal T, Barbarawi M, Zayed Y, Hicks M, Ahmed S, Bachuwa G, Hassan M, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. J Thromb Thrombolysis 2018;46(3):299–303. https://doi.org/10.1007/s11239-018-1706-2
- Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, Li X, Huang L, Johnston SC, Zhao X, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack. Circulation 2017;135(1):21–33. https://doi.org/10.1161/CIRCULATIONAHA.116.024913
- Tang XF, Zhang JH, Wang J, Han YL, Xu B, Qiao SB, Wu YJ, Chen J, Wu Y, Chen JL, et al. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J 2013;126(6):1069–1075. https://doi.org/10.3760/cma.j..0366-6999.20123360
- Verma SS, Bergmeijer TO, Gong L, Reny JL, Lewis JP, Mitchell BD, Alexopoulos D, Aradi D, Altman RB, Bliden K, et al. Genome-wide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the international clopidogrel pharmacogenomics consortium (ICPC). Clin Pharmacol Ther 2020. https://doi.org/10.1002/cpt.1911
- Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, Siller-Matula JM. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother 2017;3(4):221–234. https://doi.org/10.1093/ehjcvp/pvw044
- Xiao FY, Luo JQ, Liu M, Chen BL, Cao S, Liu ZQ, Zhou HH, Zhou G, Zhang W. Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients. Sci Rep 2017;7(1). https://doi.org/10.1038/s41598-017-07736-1
- Lewis JP, Backman JD, Reny J-L, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry J-P, Pakyz RE, Gong L, Ryan K, et al. Pharmacogenomic polygenic response score predicts ischemic events and cardiovascular mortality in clopidogrel-treated patients. Eur Heart J Cardiovasc Pharmacother 2019. https://doi.org/10.1093/ehjcvp/pvz045
- Komosa A, Siller-Matula JM, Lesiak M, Michalak M, Kowal J, MącZyński M, Siniawski A, Mularek-Kubzdela T, Wiśniewski S, Grajek S. Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention. Thromb Res 2016;138:49–54. https://doi.org/10.1016/j.thromres.2015.12.021
- Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C, Yin X, Hou Y. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis. J Cardiovasc Pharmacol Ther 2017;22(2):142–152. https://doi.org/10.1177/1074248416663647
- Pang J, Wu Q, Zhang Z, Zheng TZ, Xiang Q, Zhang P, Liu X, Zhang C, Tian Y, Huang J, et al. Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis. IJC Heart Vasculature 2019;23:100317. https://doi.org/10.1016/j.ijcha.2018.12.016
- Yi X, Han Z, Zhou Q, Cheng W, Lin J, Wang C. Concomitant use of proton-pump inhibitors and clopidogrel increases the risk of adverse outcomes in patients with Ischemic stroke carrying reduced-function CYP2C19*2. Clin Appl Thrombosis/Hemostasis 2018;24(1):55–62. https://doi.org/10.1177/1076029616669787